Manmeet Ahluwalia, Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director of Miami Cancer Institute, Baptist Health South Florida, shared a post on LinkedIn:
“Last 5 years have been particularly exhilarating in IDH-mutant glioma field! There is a now FDA approved targeted therapy and multiple novel agents in development! This offers more hope and options for our patients. How can we best personalize treatment for patients with IDH-mutant glioma?
Join me and Dr. Timothy Cloughesy SNO 2025 on November 20th 2025 during a PeerView Live Master Class and Case Forum, in partnership with the American Brain Tumor Association. The session will be both in-person and virtual, starting at 5:45 PM HST at the Hilton Hawaiian Village in Honolulu.
We’ll explore real-world strategies for using molecular therapies, including optimal treatment selection, combination approaches, and managing adverse events, while looking ahead to the evolving role of IDH inhibitors. Excited to connect with colleagues and share actionable insights for advancing neuro-oncology care. Hope to see you there!
Register here.”
More posts featuring Manmeet Ahluwalia on OncoDaily.